190.28
price down icon0.29%   -0.55
after-market After Hours: 190.28
loading
Abbvie Inc stock is traded at $190.28, with a volume of 3.78M. It is down -0.29% in the last 24 hours and up +2.64% over the past month. AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
See More
Previous Close:
$190.83
Open:
$191.4
24h Volume:
3.78M
Relative Volume:
0.59
Market Cap:
$336.11B
Revenue:
$57.37B
Net Income/Loss:
$4.20B
P/E Ratio:
80.97
EPS:
2.35
Net Cash Flow:
$15.39B
1W Performance:
+0.54%
1M Performance:
+2.64%
6M Performance:
+11.73%
1Y Performance:
+4.45%
1-Day Range:
Value
$188.53
$191.40
1-Week Range:
Value
$184.63
$192.24
52-Week Range:
Value
$163.81
$218.66

Abbvie Inc Stock (ABBV) Company Profile

Name
Name
Abbvie Inc
Name
Phone
(847) 932-7900
Name
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Name
Employee
55,000
Name
Twitter
@abbvie
Name
Next Earnings Date
2025-04-25
Name
Latest SEC Filings
Name
ABBV's Discussions on Twitter

Compare ABBV with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
ABBV
Abbvie Inc
190.28 337.08B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
LLY
Lilly Eli Co
812.69 723.06B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
168.30 407.97B 90.63B 22.66B 16.40B 9.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
117.70 227.39B 55.19B 13.65B 16.81B 6.86
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
71.70 314.28B 43.59B 15.04B 10.74B 3.3766

Abbvie Inc Stock (ABBV) Upgrades & Downgrades

Date Action Analyst Rating Change
May-14-25 Downgrade Citigroup Buy → Neutral
Apr-22-25 Initiated Cantor Fitzgerald Overweight
Dec-10-24 Resumed BofA Securities Neutral
Dec-05-24 Downgrade Daiwa Securities Outperform → Neutral
Nov-22-24 Upgrade Leerink Partners Market Perform → Outperform
Nov-15-24 Initiated Wolfe Research Outperform
Nov-04-24 Upgrade Argus Hold → Buy
Oct-17-24 Initiated Bernstein Mkt Perform
Jun-05-24 Upgrade HSBC Securities Hold → Buy
May-17-24 Initiated Cantor Fitzgerald Overweight
Jan-29-24 Upgrade William Blair Mkt Perform → Outperform
Dec-18-23 Downgrade HSBC Securities Buy → Hold
Dec-11-23 Upgrade Goldman Neutral → Buy
Nov-09-23 Initiated Deutsche Bank Hold
Oct-30-23 Upgrade Barclays Equal Weight → Overweight
Oct-20-23 Resumed UBS Neutral
Sep-29-23 Initiated Raymond James Outperform
Jul-25-23 Initiated William Blair Mkt Perform
Jul-14-23 Initiated HSBC Securities Buy
Apr-05-23 Downgrade Argus Buy → Hold
Mar-01-23 Initiated Guggenheim Buy
Feb-22-23 Downgrade Wolfe Research Outperform → Peer Perform
Feb-10-23 Upgrade SVB Securities Underperform → Market Perform
Nov-18-22 Initiated Credit Suisse Outperform
Nov-08-22 Downgrade Societe Generale Buy → Hold
Aug-01-22 Downgrade Atlantic Equities Overweight → Neutral
May-23-22 Initiated SVB Leerink Underperform
May-06-22 Downgrade Daiwa Securities Outperform → Neutral
Apr-06-22 Resumed Morgan Stanley Overweight
Feb-28-22 Downgrade UBS Buy → Neutral
Feb-03-22 Reiterated BMO Capital Markets Outperform
Feb-03-22 Reiterated Barclays Equal Weight
Feb-03-22 Reiterated BofA Securities Neutral
Feb-03-22 Reiterated Goldman Neutral
Jan-13-22 Initiated Redburn Buy
Jan-12-22 Reiterated BMO Capital Markets Outperform
Dec-09-21 Resumed Wells Fargo Overweight
Nov-23-21 Upgrade Societe Generale Hold → Buy
Jul-27-21 Resumed Truist Buy
Apr-07-21 Resumed RBC Capital Mkts Outperform
Nov-10-20 Resumed Bernstein Outperform
Sep-29-20 Initiated Berenberg Hold
Jun-23-20 Upgrade Atlantic Equities Neutral → Overweight
Jun-09-20 Upgrade Wolfe Research Peer Perform → Outperform
Jun-02-20 Upgrade Argus Hold → Buy
May-18-20 Resumed BofA/Merrill Neutral
May-12-20 Upgrade JP Morgan Neutral → Overweight
May-11-20 Resumed Morgan Stanley Overweight
Apr-20-20 Upgrade RBC Capital Mkts Sector Perform → Outperform
Mar-23-20 Downgrade Societe Generale Buy → Hold
Feb-27-20 Initiated Barclays Equal Weight
Feb-06-20 Initiated Mizuho Buy
Jan-07-20 Initiated RBC Capital Mkts Sector Perform
Dec-26-19 Reiterated Cowen Outperform
Sep-26-19 Upgrade Citigroup Neutral → Buy
Aug-20-19 Upgrade Piper Jaffray Neutral → Overweight
Jun-27-19 Upgrade Wolfe Research Underperform → Peer Perform
Jun-26-19 Upgrade SVB Leerink Mkt Perform → Outperform
May-28-19 Initiated Goldman Neutral
Apr-29-19 Upgrade BMO Capital Markets Underperform → Market Perform
View All

Abbvie Inc Stock (ABBV) Latest News

pulisher
Jul 26, 2025

AbbVie’s Phase 3 Study on Telisotuzumab Vedotin: A Potential Game-Changer in NSCLC Treatment - The Globe and Mail

Jul 26, 2025
pulisher
Jul 25, 2025

What analysts say about AbbVie Inc. stockGame-changing returns - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Is AbbVie Inc. a good long term investmentExplosive portfolio gains - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

AbbVie’s Phase 3 Study on Upadacitinib for SLE: A Potential Game Changer? - The Globe and Mail

Jul 25, 2025
pulisher
Jul 25, 2025

AbbVie’s Latest Clinical Study on Glaucoma Gel Stent: Market Implications - The Globe and Mail

Jul 25, 2025
pulisher
Jul 25, 2025

Oncology Drugs Market Insights, Competitive Landscape, and Forecast Report 2025-2032 | Immunotherapy Leads Growth in Oncology Market Due to Better Precision and Fewer Side Effects - GlobeNewswire Inc.

Jul 25, 2025
pulisher
Jul 24, 2025

What drives AbbVie Inc. stock priceExceptional portfolio growth - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

MHRA approves AbbVie’s Elahere - The Pharma Letter

Jul 24, 2025
pulisher
Jul 24, 2025

AbbVie’s Pediatric Atopic Dermatitis Study: A Potential Game-Changer? - TipRanks

Jul 24, 2025
pulisher
Jul 24, 2025

AbbVie’s Long-term Study on Bimatoprost SR: Market Implications and Study Insights - TipRanks

Jul 24, 2025
pulisher
Jul 24, 2025

September 5th Options Now Available For AbbVie (ABBV) - Nasdaq

Jul 24, 2025
pulisher
Jul 24, 2025

AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance

Jul 24, 2025
pulisher
Jul 24, 2025

The 3 Things That Matter for AbbVie Now - Yahoo Finance

Jul 24, 2025
pulisher
Jul 24, 2025

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Staar Surgical (STAA) and Universal Health (UHS) - The Globe and Mail

Jul 24, 2025
pulisher
Jul 24, 2025

Endometriosis Drugs Market Growing at Robust Expansion of the Decade: AbbVie, Pfizer, Astellas Pharma - openPR.com

Jul 24, 2025
pulisher
Jul 22, 2025

AbbVie (ABBV) Outperforms Broader Market: What You Need to Know - Yahoo Finance

Jul 22, 2025
pulisher
Jul 22, 2025

AbbVie Inc. Stock Analysis and ForecastBreakthrough profits - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Lip Fillers Market Is Booming So Rapidly 2025-2032Allergan (AbbVie Inc.), Galderma S.A., Merz Pharma - openPR.com

Jul 22, 2025
pulisher
Jul 22, 2025

Why AbbVie (ABBV) is a Strong Buy for Diversified Portfolios in a Volatile Market - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

4 Reasons To Buy AbbVie (NYSE:ABBV) - Seeking Alpha

Jul 22, 2025
pulisher
Jul 22, 2025

How Will AbbVie's Neuroscience Franchise Perform In Q2 Earnings? - Barchart.com

Jul 22, 2025
pulisher
Jul 22, 2025

How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings? - Yahoo Finance

Jul 22, 2025
pulisher
Jul 22, 2025

IGI, Abbvie team up to advance myeloma treatment ISB 2001 - Rare Cancer News

Jul 22, 2025
pulisher
Jul 22, 2025

BOTOX® Cosmetic (onabotulinumtoxinA) Selects This Year's Entrepreneurs for The Confidence Project - AbbVie News Center

Jul 22, 2025
pulisher
Jul 21, 2025

Lobbying Update: $1,160,000 of ABBVIE INC. lobbying was just disclosed - Quiver Quantitative

Jul 21, 2025
pulisher
Jul 21, 2025

AbbVie's Allergan wins $56 million in Botox patent fight - Crain's Chicago Business

Jul 21, 2025
pulisher
Jul 21, 2025

AbbVie unit wins $56 mln in US patent trial against Botox rival - Reuters

Jul 21, 2025
pulisher
Jul 21, 2025

AbbVie Unit Wins $56 Million from Revance Over Botox Patents (1) - Bloomberg Law News

Jul 21, 2025
pulisher
Jul 21, 2025

Stacey McCullough: I’m Thrilled to Join AbbVie Oncology Working in Market Access - Oncodaily

Jul 21, 2025
pulisher
Jul 21, 2025

Non-Small Cell Lung Cancer Pipeline 2025: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight | AbbVie, Xcovery, Sanofi, Pfizer, Mirati Therapeutics, AstraZeneca - Barchart.com

Jul 21, 2025
pulisher
Jul 21, 2025

AbbVie’s Promising Phase 2 Study on ADPKD Treatment: What Investors Need to Know - The Globe and Mail

Jul 21, 2025
pulisher
Jul 21, 2025

AbbVie's Q1 2025 Earnings Surge 6.5% Year-Over-Year - AInvest

Jul 21, 2025
pulisher
Jul 20, 2025

AbbVie Stock (ABBV) Opinions on Recent Price Surge and Sales Growth - Quiver Quantitative

Jul 20, 2025
pulisher
Jul 20, 2025

Morgan Stanley Reiterates a Buy Rating on AbbVie (ABBV) With a $250 PT - MSN

Jul 20, 2025
pulisher
Jul 19, 2025

AbbVie’s Phase 3 Study on Atogepant: A Potential Game-Changer for Pediatric Migraine Prevention - TipRanks

Jul 19, 2025
pulisher
Jul 18, 2025

Why AbbVie (ABBV) Remains a Dividend Standout in the Pharma Sector - MSN

Jul 18, 2025
pulisher
Jul 18, 2025

Rothschild Raises AbbVie (ABBV) Price Target, Maintains Buy Rating - MSN

Jul 18, 2025
pulisher
Jul 18, 2025

AbbVie Inc. stock underperforms Friday when compared to competitors - MarketWatch

Jul 18, 2025

Abbvie Inc Stock (ABBV) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general JNJ
$168.30
price down icon 0.74%
drug_manufacturers_general NVS
$117.70
price up icon 0.20%
drug_manufacturers_general NVO
$71.70
price up icon 1.37%
drug_manufacturers_general MRK
$84.71
price up icon 0.71%
$306.58
price down icon 0.64%
Cap:     |  Volume (24h):